Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes
Morgan E. Grams, Nigel J. Brunskill, Shoshana H. Ballew, et al.
Diabetes Care (2022) Vol. 45, Iss. 9, pp. 2055-2063
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Paul E. Stevens, Sofia B. Ahmed, Juan Jesús Carrero, et al.
Kidney International (2024) Vol. 105, Iss. 4, pp. S117-S314
Open Access | Times Cited: 1837
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association
Sadiya S. Khan, Josef Coresh, Michael Pencina, et al.
Circulation (2023) Vol. 148, Iss. 24, pp. 1982-2004
Closed Access | Times Cited: 179
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Sankar D. Navaneethan, Nisha Bansal, Kerri L. Cavanaugh, et al.
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 17
The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts
Morgan E. Grams, Nigel J. Brunskill, Shoshana H. Ballew, et al.
Journal of the American Society of Nephrology (2023)
Open Access | Times Cited: 29
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Pedro Cardoso, Katherine Young, Anand Thakarakkattil Narayanan Nair, et al.
Diabetologia (2024) Vol. 67, Iss. 5, pp. 822-836
Open Access | Times Cited: 7
Individualized Risk of CKD Progression among US Adults
Maria Clarissa Tio, Javed Butler, Xiaoqian Zhu, et al.
Journal of the American Society of Nephrology (2024) Vol. 35, Iss. 8, pp. 1076-1083
Open Access | Times Cited: 5
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
Navdeep Tangri, Thomas W. Ferguson, Ryan J. Bamforth, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3371-3380
Closed Access | Times Cited: 5
Screening for chronic kidney disease: change of perspective and novel developments
Dominique van Mil, Lyanne M. Kieneker, Hiddo J.L. Heerspink, et al.
Current Opinion in Nephrology & Hypertension (2024) Vol. 33, Iss. 6, pp. 583-592
Open Access | Times Cited: 5
Risk-directed management of chronic kidney disease
Matthew F. Blum, Brendon L. Neuen, Morgan E. Grams
Nature Reviews Nephrology (2025)
Closed Access
Risk stratification of metabolic disorder associated kidney disease
Xin Xu, Xian Shao, Fan Fan Hou
Kidney International (2025)
Closed Access
Adolescent Body Mass Index and Early Chronic Kidney Disease in Young Adulthood
Avishai M. Tsur, Inbal Akavian, Regev Landau, et al.
JAMA Pediatrics (2023) Vol. 178, Iss. 2, pp. 142-142
Closed Access | Times Cited: 12
Association of stress hyperglycemia ratio with presence and severity of chronic kidney disease among US adults with diabetes mellitus
Wenguang Lai, Yaxin Meng, Yang Zhou, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 4
THE PREVENTION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH METABOLIC SYNDROME
Doreen Zhu, Parminder K. Judge, Christoph Wanner, et al.
Kidney International (2025)
Open Access
A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
I. S. Khalimov, E. A. Polyakova, Yu. A. Shutova
Diabetes Mellitus (2025) Vol. 27, Iss. 6, pp. 620-628
Open Access
Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians
Jelle M. Beernink, Dominique van Mil, Gozewijn D. Laverman, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Filipe A. Moura, David D. Berg, Andrea Bellavia, et al.
Diabetes Care (2023) Vol. 46, Iss. 10, pp. 1807-1815
Open Access | Times Cited: 9
Chronic Kidney Disease Progression—A Challenge
Silvio Maringhini, Carmine Zoccali
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2203-2203
Open Access | Times Cited: 3
CKD Progression Prediction in a Diverse US Population: A Machine-Learning Model
Joseph Aoki, Cihan Kaya, Omar Khalid, et al.
Kidney Medicine (2023) Vol. 5, Iss. 9, pp. 100692-100692
Open Access | Times Cited: 8
Prediction models for earlier stages of chronic kidney disease
Mackenzie R. Alexiuk, Navdeep Tangri
Current Opinion in Nephrology & Hypertension (2024) Vol. 33, Iss. 3, pp. 325-330
Closed Access | Times Cited: 2
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Navdeep Tangri, Thomas W. Ferguson, Silvia J. Leon, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 1
Recommendations for European laboratories based on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Étienne Cavalier, Tomáš Zima, Pradip Datta, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2024)
Closed Access | Times Cited: 1
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration
Lesley A. Inker, Morgan E. Grams, Hrefna Guðmundsdóttir, et al.
American Journal of Kidney Diseases (2022) Vol. 80, Iss. 4, pp. 513-526
Open Access | Times Cited: 5
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Pedro Cardoso, Katherine Young, Anand Thakarakkattil Narayanan Nair, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells
Benedetta Maria Bonora, Mario Luca Morieri, Marella Marassi, et al.
Diabetologia (2023) Vol. 66, Iss. 12, pp. 2346-2355
Open Access | Times Cited: 2
Precision Medicine in Diabetic Kidney Disease: A Narrative Review Framed by Lived Experience
Mallory L. Downie, Arlene Desjarlais, Nancy Verdin, et al.
Canadian Journal of Kidney Health and Disease (2023) Vol. 10
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top